A detailed history of Alps Advisors Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 56,216 shares of ZNTL stock, worth $168,648. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,216
Previous 55,414 1.45%
Holding current value
$168,648
Previous $226,000 8.85%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.9 - $4.57 $2,325 - $3,665
802 Added 1.45%
56,216 $206,000
Q2 2024

Aug 13, 2024

BUY
$4.09 - $16.13 $21,922 - $86,456
5,360 Added 10.71%
55,414 $226,000
Q1 2024

May 14, 2024

BUY
$10.83 - $16.49 $23,252 - $35,404
2,147 Added 4.48%
50,054 $788,000
Q4 2023

Feb 14, 2024

SELL
$9.84 - $20.13 $41,505 - $84,908
-4,218 Reduced 8.09%
47,907 $725,000
Q3 2023

Nov 14, 2023

BUY
$19.63 - $28.29 $165,029 - $237,834
8,407 Added 19.23%
52,125 $1.05 Million
Q2 2023

Aug 14, 2023

BUY
$17.41 - $30.05 $761,130 - $1.31 Million
43,718 New
43,718 $1.23 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $171M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.